Insmed (INSM) – Research Analysts’ Recent Ratings Changes

A number of firms have modified their ratings and price targets on shares of Insmed (NASDAQ: INSM) recently:

  • 11/4/2026 – Insmed is now covered by HC Wainwright. They set a “buy” rating and a $220.00 price target on the stock.
  • 11/2/2026 – Insmed had its “buy” rating reaffirmed by Benchmark.
  • 11/2/2026 – Insmed had its price target lowered by Guggenheim from $205.00 to $201.00. They now have a “buy” rating on the stock.
  • 10/29/2026 – Insmed was given a new $195.00 price target by Stifel Nicolaus.
  • 10/29/2026 – Insmed was given a new $154.00 price target by Mizuho.
  • 10/27/2026 – Insmed had its “buy” rating reaffirmed by HC Wainwright.
  • 10/21/2026 – Insmed had its price target lowered by Morgan Stanley from $218.00 to $213.00. They now have an “overweight” rating on the stock.
  • 10/20/2026 – Insmed was given a new $173.00 price target by Raymond James Financial.
  • 10/15/2026 – Insmed had its “sell (d-)” rating reaffirmed by Weiss Ratings.
  • 10/12/2026 – Insmed had its “buy” rating reaffirmed by Bank of America. They now have a $207.00 price target on the stock.
  • 10/12/2026 – Insmed was downgraded by Wolfe Research from “outperform” to “peer perform”.
  • 10/12/2026 – Insmed had its “buy” rating reaffirmed by HC Wainwright. They now have a $220.00 price target on the stock.
  • 10/8/2026 – Insmed had its “buy” rating reaffirmed by UBS Group.
  • 10/6/2026 – Insmed had its “outperform” rating reaffirmed by BMO Capital Markets.
  • 9/30/2026 – Insmed had its price target lowered by Barclays from $237.00 to $207.00. They now have an “overweight” rating on the stock.
  • 9/24/2026 – Insmed is now covered by The Goldman Sachs Group. They set a “buy” rating and a $188.00 price target on the stock.
  • 9/24/2026 – Insmed is now covered by The Goldman Sachs Group. They set a “buy” rating and a $188.00 price target on the stock.

Insmed Stock Down 0.8%

Shares of Insmed stock traded down $1.03 on Tuesday, hitting $121.85. The company had a trading volume of 1,479,837 shares, compared to its average volume of 2,996,088. The firm has a market capitalization of $26.73 billion, a P/E ratio of -43.21 and a beta of 0.83. Insmed, Inc. has a twelve month low of $90.39 and a twelve month high of $212.75. The company has a debt-to-equity ratio of 0.77, a current ratio of 2.86 and a quick ratio of 2.59. The stock has a 50-day moving average of $110.75 and a 200-day moving average of $123.20.

Insmed (NASDAQ:INSM – Get Free Report) last released its earnings results on Thursday, October 29th. The biopharmaceutical company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.08). The firm had revenue of $524.43 million during the quarter, compared to the consensus estimate of $500.36 million. Insmed had a negative net margin of 39.85% and a negative return on equity of 96.38%. The company’s revenue was up 268.4% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($1.75) EPS. Research analysts predict that Insmed, Inc. will post -1.86 earnings per share for the current year.

Insider Buying and Selling at Insmed

In other Insmed news, Director David Brennan sold 25,000 shares of the company’s stock in a transaction dated Wednesday, September 9th. The stock was sold at an average price of $124.00, for a total value of $3,100,000.00. Following the transaction, the director directly owned 39,238 shares in the company, valued at $4,865,512. This represents a 38.92% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 2.10% of the stock is currently owned by corporate insiders.

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing treatments for serious diseases, including respiratory and rare conditions. The company is based in Bridgewater, New Jersey, and is led by President and Chief Executive Officer William H. Lewis Jr. Its commercial products include ARIKAYCE, an inhaled amikacin treatment for certain adults with refractory Mycobacterium avium complex lung disease, and BRINSUPRI (brensocatib), an oral treatment for non-cystic fibrosis bronchiectasis.

Read More

Receive News & Ratings for Insmed Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed Inc and related companies with MarketBeat.com's FREE daily email newsletter.